記住我
Topic: Haematological oncology
Category: Case report
Case Presentation: A 75-year-old female of Chinese descent, previously independent with a background of well-controlled hypertension, type 2 diabetes, hyperlipidemia, and mild Alzheimer’s dementia presented to the general practice with fatigue, left groin pain, decreased appetite and dizziness. She was diagnosed with end-stage MM based on serum protein electrophoresis and skeletal survey and treated with only dexamethasone as a chemotherapeutic agent.
Results: As of February 2022, two years after the diagnosis of end-stage MM and treatment with dexamethasone monotherapy and supportive therapy, the patient remains adherent to her management plan. She remained alive with mild functional decline and preserved renal function.
Conclusions: In addition to managing patients according to the best principles of supportive care, dexamethasone monotherapy may be a good alternative maintenance agent in frail, elderly patients with MM who may not even tolerate attenuated chemotherapy.
To cite this article Oey O. School of Medicine, University of Western Australia, Crawley, Western Australia, Australia , Liu Y., Sunjaya A. P. The George Institute for Global Health, Sydney, Australia Dexamethasone monotherapy in a frail and chemotherapy-ineligible patient with end-stage multiple myeloma: a case report and literature review WCRJ 2022;
9: e2429
DOI: 10.32113/wcrj_202211_2429
Submission date: 29 Sep 2022
Revised on: 10 Oct 2022
Accepted on: 19 Oct 2022
Published online: 21 Nov 2022
留言 (0)